HIGH-DOSE CYTARABINE ALONE VERSUS CYTARABINE PLUS ANTHRACYCLINE FOR CONSOLIDATION THERAPY IN NONPROMYELOCYTIC ACUTE MYELOID LEUKEMIA
So Yeon Kim, Seok Jae Huh, Ji Hyun Lee, Suee Lee, Sung Yong Oh, Hyo-Jin Kim, Dae Sik Kim, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim and Sung-Hyun Kim*
Background: Standard consolidation therapy of acute myeloid leukemia (AML) contains highdose cytarabine (HiDC). However, optimal dose of cytarabine and benefit of additional chemotherapeutic agents remain unresolved problems. Methods: 142 patients among 173 newly diagnosed AML patients, who achieved complete remission following induction chemotherapy in 4 independent institutes were retrospectively analyzed. Patients were divided into 3 groups by consolidation regimens: HiDC alone (Group A), HiDC plus anthracycline (Group B), and intermediate-dose cytarabine plus anthracycline (Group C). Results: Overall survival (OS), relapse-free survival (RFS), disease-free survival (DFS), and event-free survival (EFS) were not significantly different in Group A vs. Group B. However, Group B showed longer RFS, DFS, and EFS, as compared with Group C. In this study, the addition of anthracycline to HiDC did not survival, and had more toxicity. HiDC enhanced RFS, DFS, and EFS as compared with intermediate-dose cytarabine. Conclusions: Therefore, HiDC single therapy could be considered as standard consolidation therapy for AML.
Share this article